[Emerging visceral mycoses].
The emergence of new fungal pathogens such filamentous fungi (Scedosporium, Fusarium) or yeast (Trichosporon) is a real problem for doctors who treat immunocompromised patients. These fungi present in our environment (Scedosporium, Fusarium) can also be on the skin (Trichosporon). They are responsible for invasive infections cause of morbidity and mortality because patients are immunocompromised and the fungi are resistant to antifungal treatment. Clinical manifestations are seldom specific, but cutaneous localisations are frequent. They are either the portal of entry of the infection or a metastatic localisation. The role of laboratory for identification of the fungus is essential.
Morin
O
O
Laboratoire de parasitologie-mycologie Institut de biologie 44093 Nantes. odile.morin@chu-nantes.fr
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D003881:Dermatomycoses / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D004463:Ecology; D005670:Fusarium / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008271:Mycetoma / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D009172:Mycology / Q000379:methods; D009181:Mycoses / Q000175:diagnosis / Q000628:therapy; D011541:Pseudallescheria; D012307:Risk Factors; D021681:Scedosporium / Q000302:isolation & purification / Q000502:physiology; D014250:Trichosporon / Q000302:isolation & purification / Q000502:physiology
D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B